eived alectinib as their only ALK inhibitor, with or without prior chemotherapy
ORR = 46% (95% CI: 19, 75) in 13 patients who received ceritinib as their only ALK inhibitor, with or without prior chemotherapy
16 HOW SUPPLIED/STORAGE AND HANDLING
Table 7 describes the available strengths and package configurations for LORBRENA:
Table 7 LORBRENA Tablets
tablets
25mg 30tablets NDC:0069-0227-01
100mg 30tablets NDC:0069-0231-01
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
|
